Skye Bioscience, Inc.
General ticker "SKYE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $113.8M (TTM average)
Skye Bioscience, Inc. follows the US Stock Market performance with the rate: 16.6%.
Estimated limits based on current volatility of 3.7%: low 1.15$, high 1.25$
Factors to consider:
- Total employees count: 11 (0.0%) as of 2023
- Top business risk factors: Economic downturns and volatility, Operational and conduct risks, Market competition, Regulatory and compliance, Labor/talent shortage/retention
- Current price 12.8% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.39$, 4.77$]
- 2025-12-31 to 2026-12-31 estimated range: [1.03$, 3.44$]
Financial Metrics affecting the SKYE estimates:
- Positive: with PPE of -3.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -25.67 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of -0.25 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: Shareholder equity ratio, % of 93.66 > 63.39
Short-term SKYE quotes
Long-term SKYE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $18.31MM | $34.74MM | $30.19MM |
| Operating Income | $-18.31MM | $-34.74MM | $-30.19MM |
| Non-Operating Income | $-1.16MM | $-2.91MM | $3.64MM |
| Interest Expense | $0.67MM | $0.91MM | $0.97MM |
| R&D Expense | $6.01MM | $5.82MM | $18.70MM |
| Income(Loss) | $-19.47MM | $-37.64MM | $-26.56MM |
| Taxes | $0.01MM | $0.00MM | $0.01MM |
| Profit(Loss)* | $-19.48MM | $-37.64MM | $-26.57MM |
| Stockholders Equity | $-3.01MM | $-2.13MM | $68.15MM |
| Assets | $9.11MM | $11.94MM | $72.76MM |
| Operating Cash Flow | $-12.74MM | $-13.95MM | $-25.24MM |
| Capital expenditure | $0.03MM | $0.01MM | $1.60MM |
| Investing Cash Flow | $5.21MM | $6.60MM | $-0.25MM |
| Financing Cash Flow | $-0.21MM | $16.44MM | $83.56MM |
| Earnings Per Share** | $-8.77 | $-5.37 | $-0.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.